Skip to main content
Premium Trial:

Request an Annual Quote

Sysmex Inostics SafeSeq Breast Cancer and Head and Neck Panels, SafeSeq Rapid Custom Development Program

Sysmex Inostics has launched its SafeSeq Breast Cancer and Head and Neck Cancer Panels, which both run on the firm's next-generation sequencing SafeSeq platform. The SafeSeq Breast Cancer Panel tests for mutations affecting the PIK3CA, ESR1, TP53, ERBB2, AKT1, and KRAS genes in ER-positive HER2-negative breast cancer samples, the firm noted. The SafeSEQ Breast cancer panel offers sensitive detection of mutant ctDNA, which Sysmex believes is well suited for disease monitoring to assess treatment response, minimal residual disease, and molecular relapse. Sysmex's SafeSeq Head and Neck Cancer panel tests for mutations in the genes PIK3CA, CDKN2A, HRAS, and TP53. 

In addition to the cancer panels, Sysmex now offers its SafeSeq Rapid Custom Development program for circulating tumor DNA (ctDNA) analysis. The firm said that users can assemble targeted genes and mutations into highly sensitive fit-for-purpose assays with customer-selected levels of analytical and clinical validation.

The Scan

RNA Editing in Octopuses Seems to Help Acclimation to Shifts in Water Temperature

A paper in Cell reports that octopuses use RNA editing to help them adjust to different water temperatures.

Topical Compound to Block EGFR Inhibitors May Ease Skin Toxicities, Study Finds

A topical treatment described in Science Translational Medicine may limit skin toxicities seen with EGFR inhibitor therapy.

Dozen Genetic Loci Linked to Preeclampsia Risk in New GWAS

An analysis of genome-wide association study data in JAMA Cardiology finds genetic loci linked to preeclampsia that have ties to blood pressure.

Cancer Survival Linked to Mutational Burden in Pan-Cancer Analysis

A pan-cancer paper appearing in JCO Precision Oncology suggests tumor mutation patterns provide clues for predicting cancer survival that are independent of other prognostic factors.